Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 11

Future Perspectives on ADCs in Breast Cancer

September 24, 2024

Panelists discuss how ongoing clinical trials of investigational antibody-drug conjugates (ADCs) are advancing treatment options for breast cancer, particularly in patients with active brain metastases and advanced disease.

EP. 1: Overview of Current ADCs in Breast Cancer

EP. 2: ADCs in Breast Cancer: Mechanism of Action, and Components

EP. 3: Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials

EP. 4: Expert Perspectives on the Management of SG-Related Neutropenia

EP. 5: Navigating SG-related Diarrhea

EP. 6: Expert Insights: SG Adverse Events Management including Alopecia & Nausea

EP. 7: Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies

EP. 8: Clinical Management Considerations: Pneumonitis associated with T-DXd

EP. 9: Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

EP. 10: Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer

Now Viewing

EP. 11: Future Perspectives on ADCs in Breast Cancer

EP. 12: Expert Insights: Investigational ADCs Safety Profiles

Video content above is prompted by the following:

Please review some ongoing clinical trials and studies utilizing investigational ADCs in breast cancer that are in progress that may be interesting. (See below for a few suggestions. Please include others if not included.)
1.Bartsch R. et al. Patritumab deruxtecan (HER3-DXd) in Active Brain Mets. TUXEDO-3 Phase II trial. ASCO 2024 Abstract
2.Bardia A et al, Final Results TROPION-Breast01. ESMO 2023 Abstract.